501 related articles for article (PubMed ID: 31094016)
1. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
[TBL] [Abstract][Full Text] [Related]
2. Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients.
Liu J; Ma Y; Han P; Wang J; Liu YG; Shi RF; Li J
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101957. PubMed ID: 35609821
[TBL] [Abstract][Full Text] [Related]
3. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
5. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease.
Shen F; Zheng RD; Shi JP; Mi YQ; Chen GF; Hu X; Liu YG; Wang XY; Pan Q; Chen GY; Chen JN; Xu L; Zhang RN; Xu LM; Fan JG
Liver Int; 2015 Nov; 35(11):2392-400. PubMed ID: 25689614
[TBL] [Abstract][Full Text] [Related]
6. A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
Cai YJ; Dong JJ; Wang XD; Huang SS; Chen RC; Chen Y; Wang YQ; Song M; Chen YP; Li Z; Zhou MT; Shi KQ
J Viral Hepat; 2017 Nov; 24(11):1005-1015. PubMed ID: 28419755
[TBL] [Abstract][Full Text] [Related]
7. Controlled attenuation parameter value-based diagnostic algorithm improves the accuracy of liver stiffness measurement in chronic hepatitis B patients.
Fan Y; Wang L; Ding Y; Sheng Q; Zhang C; Li Y; Han C; Dou X
Aging (Albany NY); 2020 Aug; 12(16):16072-16082. PubMed ID: 32836216
[TBL] [Abstract][Full Text] [Related]
8. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
[TBL] [Abstract][Full Text] [Related]
9. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
Wan T; Köhn N; Kröll D; Berzigotti A
Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
[TBL] [Abstract][Full Text] [Related]
10. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
[TBL] [Abstract][Full Text] [Related]
11. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
[TBL] [Abstract][Full Text] [Related]
12. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Steatosis in Chronic Hepatitis B as Measured by Controlled Attenuation Parameter: Frequency and Distribution.
Nan S; Liang Y; Qu Y; Liu F; Wang L; Li T
J Coll Physicians Surg Pak; 2019 Oct; 29(10):937-941. PubMed ID: 31564265
[TBL] [Abstract][Full Text] [Related]
14. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
Lee JI; Lee HW; Lee KS
World J Gastroenterol; 2019 Sep; 25(33):4959-4969. PubMed ID: 31543686
[TBL] [Abstract][Full Text] [Related]
15. Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B.
Seto WK; Hui RWH; Mak LY; Fung J; Cheung KS; Liu KSH; Wong DK; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):575-583.e2. PubMed ID: 28970146
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B.
Wang CY; Lu W; Hu DS; Wang GD; Cheng XJ
World J Gastroenterol; 2014 Aug; 20(30):10585-90. PubMed ID: 25132779
[TBL] [Abstract][Full Text] [Related]
17. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.
Baumeler S; Jochum W; Neuweiler J; Bergamin I; Semela D
Swiss Med Wkly; 2019 Apr; 149():w20077. PubMed ID: 31026041
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
19. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
[TBL] [Abstract][Full Text] [Related]
20. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
